Search
Probucol
go.drugbank.com/drugs/DB01599ApprovedInvestigationalWithdrawnA drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Diacerein
go.drugbank.com/drugs/DB11994ApprovedInvestigationalWithdrawnDiacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is und...
Alphameprodine
go.drugbank.com/drugs/DB01499ExperimentalIllicitAlphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.
Betameprodine
go.drugbank.com/drugs/DB01552ExperimentalIllicitBetameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.
Imidacloprid
go.drugbank.com/drugs/DB11421ExperimentalVet approvedImidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise
Orgotein
go.drugbank.com/drugs/DB11444ExperimentalVet approvedHydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum.
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with
Totrombopag
go.drugbank.com/drugs/DB05930InvestigationalThis drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding
1-Deoxy-D-xylulose 5-phosphate
go.drugbank.com/drugs/DB02496ExperimentalThese are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System